Immunic (IMUX)

• Market cap: $73.8M
• 1 day: -1.26%
• 5 days: -7.02%
• 1 month: -15.93%
• 3 months: -20.63%
• 6 months: -25.2%
• Year to date: -39.83%
• 1 year: -44.71%
• 5 years: -96.7%
• 10 years: -99.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Employees: 90